CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TADA2A (ImmuneEditome ID:6871)

1. Gene summary of enriched editing regions for TADA2A

check button Gene summary
Gene informationGene symbol

TADA2A

Gene ID

6871

GeneSynonymsADA2|ADA2A|KL04P|TADA2L|hADA2
GeneCytomap

17q12

GeneTypeprotein-coding
GeneDescriptiontranscriptional adapter 2-alpha|ADA2-like protein|transcriptional adaptor 2 alpha
GeneModificationdate20230517
UniprotIDO75478;A0A087WWR4;A0A087X2C8;A0A024R0Y4;A0A087WTV5;A0A0J9YWZ4;A0A087WU71;A0A0J9YXZ4;A0A087WZS1;A0A0S2Z4G1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:37411513-37412139:+ENST00000610834.3ENSG00000276234.3TADA2AncRNA_intronicAluY,AluSxchr17:37411513-37412139:+.alignment
chr17:37411513-37412139:+ENST00000620838.3ENSG00000276234.3TADA2AncRNA_intronicAluY,AluSxchr17:37411513-37412139:+.alignment
chr17:37428572-37429520:+ENST00000610834.3ENSG00000276234.3TADA2AncRNA_intronic(TTTA)n,AluY,MLT1E2,MLT2C1,AluJbchr17:37428572-37429520:+.alignment
chr17:37428572-37429520:+ENST00000620838.3ENSG00000276234.3TADA2AncRNA_intronic(TTTA)n,AluY,MLT1E2,MLT2C1,AluJbchr17:37428572-37429520:+.alignment
chr17:37442963-37444187:+ENST00000620086.3ENSG00000276234.3TADA2AncRNA_intronicMER58A,AluJo,AluJb,AluSq2chr17:37442963-37444187:+.alignment
chr17:37446460-37447590:+ENST00000620086.3ENSG00000276234.3TADA2AncRNA_intronicFLAM_C,AluSz6chr17:37446460-37447590:+.alignment
chr17:37451112-37451437:+ENST00000619335.3ENSG00000276234.3TADA2AncRNA_intronicAluJr4,AluJbchr17:37451112-37451437:+.alignment
chr17:37451112-37451437:+ENST00000620086.3ENSG00000276234.3TADA2AncRNA_intronicAluJr4,AluJbchr17:37451112-37451437:+.alignment
chr17:37459508-37460946:+ENST00000619335.3ENSG00000276234.3TADA2AncRNA_intronicAluSx,(TGTA)n,AluJr,FLAM_A,AluSzchr17:37459508-37460946:+.alignment
chr17:37459508-37460946:+ENST00000620086.3ENSG00000276234.3TADA2AncRNA_intronicAluSx,(TGTA)n,AluJr,FLAM_A,AluSzchr17:37459508-37460946:+.alignment
chr17:37477477-37478150:+ENST00000622085.1ENSG00000276234.3TADA2AncRNA_exonicAluSg,AluSq2chr17:37477477-37478150:+.alignment


Top

2. Tumor-specific enriched editing regions for TADA2A


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr17:37477477-37478150:+BRCAEER3.4280e-08image
ENSG00000276234.3,TADA2ABRCAEAG2.3182e-08image
chr17:37477477-37478150:+HNSCEER1.1783e-03image
ENSG00000276234.3,TADA2AHNSCEAG1.1783e-03image
chr17:37477477-37478150:+KICHEER4.7187e-03image
ENSG00000276234.3,TADA2AKICHEAG4.7187e-03image
chr17:37477477-37478150:+LUADEER4.2589e-02image
ENSG00000276234.3,TADA2ALUADEAG4.1456e-02image
chr17:37477477-37478150:+THCAEER9.1435e-06image
ENSG00000276234.3,TADA2ATHCAEAG9.1435e-06image
chr17:37477477-37478150:+UCECEER6.4263e-03image
ENSG00000276234.3,TADA2AUCECEAG6.8769e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000276234.3,TADA2ACOADPathEAG3.6502e-023.8531e-02-0.1044image
ENSG00000276234.3,TADA2ATHCAPathEAG2.7480e-024.9286e-020.0877image
chr17:37477477-37478150:+THCAPathEER2.7480e-024.9286e-020.0877image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr17:37477477-37478150:+COADEER4.3157e-023.0540e-028.0237e+00image
ENSG00000276234.3,TADA2ACOADEAG4.3157e-023.0540e-028.0237e+00image

Top

3. Enriched editing regions and immune related genes for TADA2A


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:37477477-37478150:+COADEERENSG00000091039,OSBPL80.25962.1882e-031.3600e-220.5606imageNFBL;IGF2BP2NANeutrophilsGSVA_HALLMARK_DNA_REPAIR
chr17:37477477-37478150:+COADEERENSG00000139324,TMTC30.24113.7317e-033.6692e-190.5203imageNFBL;IGF2BP2NAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr17:37477477-37478150:+COADEERENSG00000152332,UHMK10.22847.8505e-031.0565e-140.4584imageNFBL;IGF2BP2NAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr17:37477477-37478150:+COADEERENSG00000177888,ZBTB410.21911.1550e-022.4920e-150.4679imageNFBL;IGF2BP2NAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr17:37477477-37478150:+COADEERENSG00000165476,REEP30.22061.1635e-028.2174e-120.4102imageNFBL;IGF2BP2NANeutrophilsGSVA_HALLMARK_DNA_REPAIR
chr17:37477477-37478150:+COADEERENSG00000251869,SCARNA230.15141.7418e-021.1106e-130.4422imageNNNAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr17:37477477-37478150:+COADEERENSG00000166128,RAB8B0.20871.8710e-021.2578e-150.4723imageNFBL;IGF2BP2NANeutrophilsGSVA_HALLMARK_DNA_REPAIR
chr17:37477477-37478150:+COADEERENSG00000070367,EXOC50.20861.9271e-027.7227e-120.4107imageNFBL;IGF2BP2EXOC5EosinophilsGSVA_HALLMARK_P53_PATHWAY
chr17:37477477-37478150:+COADEERENSG00000117505,DR10.20731.9846e-026.2886e-130.4297imageNFBL;IGF2BP2DR1EosinophilsGSVA_HALLMARK_P53_PATHWAY
chr17:37477477-37478150:+COADEERENSG00000085832,EPS150.20562.1351e-021.1444e-120.4253imageNFBL;IGF2BP2NAEosinophilsGSVA_HALLMARK_DNA_REPAIR

More results



Top

4. Enriched editing regions and immune related splicing for TADA2A


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000276234.3,TADA2A
COADEAGIRENSG00000142541.12chr1949489848:49489912:49490231:494902970.25541.1261e-028.9626e-120.4074imageNACIN1;ADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDF1;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr17:37477477-37478150:+
COADEERMEXENSG00000165282.9chr935090465:35090672:35091239:35092767:35095054:35095566:35096560:35096576-0.24591.4071e-021.4734e-11-0.4056imageNFBL;IGF2BP2NANeutrophilsGSVA_HALLMARK_DNA_REPAIR
ENSG00000276234.3,TADA2A
COADEAGIRENSG00000116679.11chr1185301433:185306625:185307013:1853071390.22444.2965e-021.3595e-110.4085imageNACIN1;ADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;ZC3H7B;ZNF184NANeutrophilsGSVA_HALLMARK_PEROXISOME
ENSG00000276234.3,TADA2A
COADEAGA3ENSG00000160201.7chr2143104314:43104402:43100452:43100519:43100452:43101432-0.27594.2470e-031.5391e-13-0.4376imageNACIN1;ADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDF1;ZC3H7B;ZNF184NANeutrophilsGSVA_HALLMARK_P53_PATHWAY
chr17:37477477-37478150:+
COADEERA3ENSG00000160201.7chr2143104314:43104402:43100452:43100519:43100452:43101432-0.24961.4682e-021.3636e-12-0.4240imageNFBL;IGF2BP2NANeutrophilsGSVA_HALLMARK_P53_PATHWAY
ENSG00000276234.3,TADA2A
COADEAGA5ENSG00000188846.9chr340457889:40457991:40457362:40457363:40457362:40457747-0.25361.2966e-024.0859e-14-0.4468imageNACIN1;ADAR;AIFM1;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr17:37477477-37478150:+
COADEERIRENSG00000187742.10chr989338457:89338580:89339863:893399470.22983.1893e-023.4891e-220.5561imageNFBL;IGF2BP2NAEosinophilsGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr17:37477477-37478150:+
COADEERIRENSG00000142541.12chr1949489848:49489912:49490231:494902970.23023.2819e-021.6581e-180.5120imageNFBL;IGF2BP2NAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr17:37477477-37478150:+
COADEERA5ENSG00000188846.9chr340457889:40457991:40457362:40457363:40457362:40457747-0.23013.4144e-023.7332e-17-0.4940imageNFBL;IGF2BP2NAEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr17:37477477-37478150:+
COADEERIRENSG00000036549.8chr177640953:77641446:77641521:776416550.19201.1372e-025.1695e-180.5546imageNFBL;IGF2BP2NANeutrophilsGSVA_HALLMARK_P53_PATHWAY

More results



Top

5. Enriched editing regions and immune infiltration for TADA2A


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr17:37477477-37478150:+ACCEERNK_cells_activated2.9341e-020.2747image
ENSG00000276234.3,TADA2AACCEAGNK_cells_activated2.9341e-020.2747image
chr17:37477477-37478150:+BLCAEERMacrophages_M13.2861e-070.2535image
ENSG00000276234.3,TADA2ABLCAEAGMacrophages_M13.6285e-070.2523image
chr17:37477477-37478150:+BRCAEERNeutrophils1.0908e-030.1013image
ENSG00000276234.3,TADA2ABRCAEAGNeutrophils1.5606e-030.0978image
chr17:37477477-37478150:+CHOLEERDendritic_cells_activated1.5275e-020.4188image
ENSG00000276234.3,TADA2ACHOLEAGDendritic_cells_activated1.5275e-020.4188image
chr17:37477477-37478150:+COADEERNeutrophils4.5182e-040.2177image
ENSG00000276234.3,TADA2ACOADEAGEosinophils8.4898e-030.1632image
chr17:37477477-37478150:+DLBCEERDendritic_cells_resting3.5960e-030.4122image
ENSG00000276234.3,TADA2ADLBCEAGDendritic_cells_resting3.5960e-030.4122image
chr17:37477477-37478150:+ESCAEERMacrophages_M21.8057e-020.1928image
ENSG00000276234.3,TADA2AESCAEAGMacrophages_M22.4460e-020.1831image
chr17:37477477-37478150:+GBMEERB_cells_memory4.8535e-02-0.1534image
ENSG00000276234.3,TADA2AGBMEAGB_cells_memory4.7682e-02-0.1539image
chr17:37477477-37478150:+HNSCEERT_cells_regulatory_(Tregs)1.4147e-03-0.1549image
ENSG00000276234.3,TADA2AHNSCEAGT_cells_regulatory_(Tregs)1.4147e-03-0.1549image
chr17:37477477-37478150:+KICHEERT_cells_CD4_memory_resting1.9479e-020.2984image
ENSG00000276234.3,TADA2AKICHEAGT_cells_CD4_memory_resting1.9479e-020.2984image
chr17:37477477-37478150:+KIRCEERNK_cells_activated1.5753e-03-0.1674image
ENSG00000276234.3,TADA2AKIRCEAGNK_cells_activated1.5800e-03-0.1673image
chr17:37477477-37478150:+KIRPEERMast_cells_resting1.7820e-02-0.1444image
ENSG00000276234.3,TADA2AKIRPEAGMast_cells_resting1.8888e-02-0.1431image
ENSG00000276234.3,TADA2ALAMLEAGT_cells_regulatory_(Tregs)1.7231e-030.4542image
chr17:37477477-37478150:+LIHCEERT_cells_gamma_delta2.3269e-030.1965image
ENSG00000276234.3,TADA2ALIHCEAGT_cells_gamma_delta2.3269e-030.1965image
chr17:37477477-37478150:+LUADEERMast_cells_activated1.2152e-030.1486image
ENSG00000276234.3,TADA2ALUADEAGMast_cells_activated1.0928e-030.1498image
chr17:37477477-37478150:+LUSCEERNK_cells_resting4.1854e-040.1619image
ENSG00000276234.3,TADA2ALUSCEAGNK_cells_resting4.2252e-040.1618image
chr17:37477477-37478150:+MESOEEREosinophils4.3626e-020.2276image
ENSG00000276234.3,TADA2AMESOEAGEosinophils4.3626e-020.2276image
chr17:37477477-37478150:+PAADEERMacrophages_M14.1476e-030.2188image
ENSG00000276234.3,TADA2APAADEAGMacrophages_M14.1476e-030.2188image
chr17:37477477-37478150:+PCPGEERT_cells_gamma_delta3.4339e-040.2684image
ENSG00000276234.3,TADA2APCPGEAGT_cells_gamma_delta3.4339e-040.2684image
chr17:37477477-37478150:+READEERNeutrophils6.5112e-030.2788image
ENSG00000276234.3,TADA2AREADEAGNeutrophils6.5112e-030.2788image
chr17:37477477-37478150:+SARCEERMacrophages_M11.5226e-040.2387image
ENSG00000276234.3,TADA2ASARCEAGMacrophages_M11.5206e-040.2387image
chr17:37477477-37478150:+SKCMEERT_cells_CD83.2743e-040.1703image
ENSG00000276234.3,TADA2ASKCMEAGT_cells_CD83.2743e-040.1703image
chr17:37446460-37447590:+STADEERT_cells_CD85.1218e-030.5524image
chr17:37459508-37460946:+STADEERB_cells_naive2.5537e-020.3038image
chr17:37477477-37478150:+STADEERT_cells_CD4_memory_resting7.1784e-03-0.1570image
ENSG00000276234.3,TADA2ASTADEAGT_cells_CD4_memory_resting2.4777e-03-0.1753image
chr17:37477477-37478150:+TGCTEERMacrophages_M26.3652e-08-0.4165image
ENSG00000276234.3,TADA2ATGCTEAGMacrophages_M26.3836e-08-0.4165image
chr17:37477477-37478150:+THCAEERT_cells_CD4_memory_activated6.6177e-040.1512image
ENSG00000276234.3,TADA2ATHCAEAGT_cells_CD4_memory_activated6.6177e-040.1512image
chr17:37477477-37478150:+THYMEERMacrophages_M13.1392e-110.5633image
ENSG00000276234.3,TADA2ATHYMEAGMacrophages_M13.1392e-110.5633image
chr17:37477477-37478150:+UCECEERDendritic_cells_activated2.7448e-020.1667image
ENSG00000276234.3,TADA2AUCECEAGDendritic_cells_activated1.9993e-020.1758image


Top

6. Enriched editing regions and immune gene sets for TADA2A


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr17:37477477-37478150:+HNSCEER3.6499e-02image1.9851e-020.1134image
ENSG00000276234.3,TADA2AHNSCEAG3.6499e-02image1.9851e-020.1134image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr17:37477477-37478150:+BLCAEER5.6852e-050.20113.8190e-030.14521.0928e-050.21937.9083e-090.2852image
ENSG00000276234.3,TADA2ABLCAEAG6.5352e-050.19923.4625e-030.14661.0428e-050.21951.6731e-080.2788image
chr17:37477477-37478150:+THYMEER6.7164e-04-0.30871.8369e-04-0.33782.4547e-060.41827.2983e-090.5014image
ENSG00000276234.3,TADA2ATHYMEAG6.7164e-04-0.30871.8369e-04-0.33782.4547e-060.41827.2983e-090.5014image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr17:37477477-37478150:+BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER8.6877e-130.3494image
ENSG00000276234.3,TADA2ABLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.1176e-120.3434image
ENSG00000276234.3,TADA2ABRCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.4214e-130.2262image
chr17:37477477-37478150:+BRCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER9.7149e-150.2373image
ENSG00000276234.3,TADA2ACESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.0249e-040.2123image
chr17:37477477-37478150:+CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.0249e-040.2123image
ENSG00000276234.3,TADA2ACHOLGSVA_HALLMARK_PROTEIN_SECRETIONEAG3.6677e-020.3651image
chr17:37477477-37478150:+CHOLGSVA_HALLMARK_PROTEIN_SECRETIONEER3.6677e-020.3651image
ENSG00000276234.3,TADA2ACOADGSVA_HALLMARK_DNA_REPAIREAG4.9487e-03-0.1741image
chr17:37477477-37478150:+COADGSVA_HALLMARK_DNA_REPAIREER8.6335e-03-0.1638image
ENSG00000276234.3,TADA2AESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG2.9058e-020.1777image
ENSG00000276234.3,TADA2AHNSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG7.7364e-090.2764image
chr17:37477477-37478150:+HNSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER7.7364e-090.2764image
chr17:37477477-37478150:+KIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER5.0074e-060.2399image
ENSG00000276234.3,TADA2AKIRCGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG5.0487e-060.2398image
chr17:37477477-37478150:+KIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.4211e-030.1842image
ENSG00000276234.3,TADA2AKIRPGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.7183e-030.1821image
ENSG00000276234.3,TADA2ALAMLGSVA_HALLMARK_UV_RESPONSE_DNEAG1.6707e-020.3550image
chr17:37477477-37478150:+LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.6449e-060.2068image
ENSG00000276234.3,TADA2ALGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6449e-060.2068image
chr17:37477477-37478150:+LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.6548e-040.2418image
ENSG00000276234.3,TADA2ALIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.6548e-040.2418image
ENSG00000276234.3,TADA2ALUADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG6.6414e-070.2265image
chr17:37477477-37478150:+LUADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.1688e-060.2218image
ENSG00000276234.3,TADA2ALUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.0583e-070.2420image
chr17:37477477-37478150:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0450e-070.2421image
chr17:37477477-37478150:+MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER8.8159e-060.4770image
ENSG00000276234.3,TADA2AMESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG8.8159e-060.4770image
chr17:37477477-37478150:+OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.5354e-02-0.1235image
ENSG00000276234.3,TADA2AOVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.5424e-020.1235image
ENSG00000276234.3,TADA2APAADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG1.9836e-020.1785image
chr17:37477477-37478150:+PAADGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER1.9836e-020.1785image
chr17:37477477-37478150:+PCPGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER7.2237e-040.2539image
ENSG00000276234.3,TADA2APCPGGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG7.2237e-040.2539image
chr17:37477477-37478150:+READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.0322e-020.2236image
ENSG00000276234.3,TADA2AREADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.0322e-020.2236image
ENSG00000276234.3,TADA2ASARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.9905e-050.2503image
chr17:37477477-37478150:+SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.9946e-050.2502image
chr17:37477477-37478150:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.6217e-060.2260image
ENSG00000276234.3,TADA2ASKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6217e-060.2260image
chr17:37446460-37447590:+STADGSVA_HALLMARK_HYPOXIAEER3.9686e-040.6646image
chr17:37411513-37412139:+STADGSVA_HALLMARK_ADIPOGENESISEER3.3932e-020.3884image
chr17:37428572-37429520:+STADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER3.9570e-02-0.3657image
chr17:37477477-37478150:+STADGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER2.0432e-020.1356image
chr17:37459508-37460946:+STADGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER1.0369e-020.3461image
ENSG00000276234.3,TADA2ASTADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG4.6452e-030.1641image
chr17:37477477-37478150:+TGCTGSVA_HALLMARK_ANGIOGENESISEER1.1217e-07-0.4093image
ENSG00000276234.3,TADA2ATGCTGSVA_HALLMARK_ANGIOGENESISEAG1.1260e-07-0.4093image
ENSG00000276234.3,TADA2ATHCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEAG7.9946e-090.2534image
chr17:37477477-37478150:+THCAGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER7.9946e-090.2534image
chr17:37477477-37478150:+THYMGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER7.8746e-110.5537image
ENSG00000276234.3,TADA2ATHYMGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG7.8746e-110.5537image
chr17:37477477-37478150:+UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.7639e-030.2079image
ENSG00000276234.3,TADA2AUCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.9467e-030.2235image
ENSG00000276234.3,TADA2AUCSGSVA_HALLMARK_MYOGENESISEAG1.4685e-02-0.3245image
chr17:37477477-37478150:+UCSGSVA_HALLMARK_MYOGENESISEER1.4685e-02-0.3245image
ENSG00000276234.3,TADA2AUVMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG2.1815e-02-0.2700image
chr17:37477477-37478150:+UVMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER2.1815e-02-0.2700image


Top

7. Enriched editing regions and drugs for TADA2A


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr17:37477477-37478150:+ACCCamptothecinEER1.2103e-020.3144image
ENSG00000276234.3,TADA2AACCCamptothecinEAG1.2103e-020.3144image
ENSG00000276234.3,TADA2ABLCAAICAREAG2.7549e-09-0.2931image
chr17:37477477-37478150:+BLCAAICAREER4.6838e-09-0.2893image
chr17:37477477-37478150:+BRCAEHT.1864EER5.0583e-050.1255image
ENSG00000276234.3,TADA2ABRCAEHT.1864EAG4.9688e-050.1253image
chr17:37477477-37478150:+CESCAZD6244EER1.1789e-03-0.1858image
ENSG00000276234.3,TADA2ACESCAZD6244EAG1.1789e-03-0.1858image
chr17:37477477-37478150:+CHOLAMG.706EER2.6677e-030.5059image
ENSG00000276234.3,TADA2ACHOLAMG.706EAG2.6677e-030.5059image
ENSG00000276234.3,TADA2ACOADBMS.708163EAG6.6646e-05-0.2452image
chr17:37477477-37478150:+COADGW843682XEER6.4886e-060.2777image
ENSG00000276234.3,TADA2ADLBCAZD8055EAG2.2431e-04-0.5085image
chr17:37477477-37478150:+DLBCAZD8055EER2.2431e-04-0.5085image
ENSG00000276234.3,TADA2AESCAAP.24534EAG2.5258e-03-0.2441image
chr17:37477477-37478150:+ESCAImatinibEER5.4280e-03-0.2260image
chr17:37477477-37478150:+GBMAP.24534EER2.9329e-03-0.2295image
ENSG00000276234.3,TADA2AGBMAP.24534EAG2.9318e-03-0.2295image
chr17:37477477-37478150:+HNSCCI.1040EER3.5475e-09-0.2824image
ENSG00000276234.3,TADA2AHNSCCI.1040EAG3.5475e-09-0.2824image
chr17:37477477-37478150:+KICHGDC.0449EER2.7080e-020.2831image
ENSG00000276234.3,TADA2AKICHGDC.0449EAG2.7080e-020.2831image
chr17:37477477-37478150:+KIRCBMS.708163EER7.0395e-05-0.2097image
ENSG00000276234.3,TADA2AKIRCBMS.708163EAG7.0763e-05-0.2096image
chr17:37477477-37478150:+KIRPCCT018159EER6.4654e-040.2067image
ENSG00000276234.3,TADA2AKIRPCCT018159EAG6.1324e-040.2076image
ENSG00000276234.3,TADA2ALAMLBMS.509744EAG2.3316e-020.3376image
chr17:37477477-37478150:+LGGBicalutamideEER3.7867e-06-0.1996image
ENSG00000276234.3,TADA2ALGGBicalutamideEAG3.7867e-06-0.1996image
ENSG00000276234.3,TADA2ALIHCGefitinibEAG1.2365e-04-0.2520image
chr17:37477477-37478150:+LIHCGefitinibEER1.2365e-04-0.2520image
ENSG00000276234.3,TADA2ALUADGemcitabineEAG1.3819e-09-0.2742image
chr17:37477477-37478150:+LUADGemcitabineEER1.1995e-09-0.2755image
ENSG00000276234.3,TADA2ALUSCAUY922EAG1.1956e-06-0.2216image
chr17:37477477-37478150:+LUSCAUY922EER1.1484e-06-0.2219image
chr17:37477477-37478150:+MESODMOGEER1.1974e-03-0.3580image
ENSG00000276234.3,TADA2AMESODMOGEAG1.1974e-03-0.3580image
ENSG00000276234.3,TADA2AOVABT.263EAG6.6391e-030.1670image
chr17:37477477-37478150:+OVABT.263EER6.5349e-030.1673image
chr17:37477477-37478150:+PAADBicalutamideEER1.7392e-03-0.2427image
ENSG00000276234.3,TADA2APAADBicalutamideEAG1.7392e-03-0.2427image
ENSG00000276234.3,TADA2APCPGBosutinibEAG3.0611e-040.2705image
chr17:37477477-37478150:+PCPGBosutinibEER3.0611e-040.2705image
chr17:37477477-37478150:+PRADJNJ.26854165EER2.2480e-020.1039image
ENSG00000276234.3,TADA2APRADBIBW2992EAG1.8837e-020.1070image
chr17:37477477-37478150:+READGDC.0449EER2.2950e-02-0.2344image
ENSG00000276234.3,TADA2AREADGDC.0449EAG2.2950e-02-0.2344image
ENSG00000276234.3,TADA2ASARCAP.24534EAG1.2098e-04-0.2422image
chr17:37477477-37478150:+SARCAP.24534EER1.2118e-04-0.2421image
chr17:37477477-37478150:+SKCMDMOGEER6.8190e-04-0.1612image
ENSG00000276234.3,TADA2ASKCMDMOGEAG6.8190e-04-0.1612image
chr17:37446460-37447590:+STADDasatinibEER7.2763e-03-0.5441image
chr17:37477477-37478150:+STADEmbelinEER1.5349e-02-0.1418image
chr17:37411513-37412139:+STADKU.55933EER1.0720e-02-0.4590image
ENSG00000276234.3,TADA2ASTADAZD7762EAG5.6553e-03-0.1605image
chr17:37428572-37429520:+STADA.770041EER1.2713e-03-0.5524image
chr17:37459508-37460946:+STADAG.014699EER3.4949e-03-0.3906image
ENSG00000276234.3,TADA2ATGCTIPA.3EAG3.1081e-06-0.3635image
chr17:37477477-37478150:+TGCTIPA.3EER3.0926e-06-0.3635image
ENSG00000276234.3,TADA2ATHCACI.1040EAG4.2696e-08-0.2411image
chr17:37477477-37478150:+THCACI.1040EER4.2696e-08-0.2411image
chr17:37477477-37478150:+THYMIPA.3EER1.3380e-110.5719image
ENSG00000276234.3,TADA2ATHYMIPA.3EAG1.3380e-110.5719image
chr17:37477477-37478150:+UCECEHT.1864EER1.7250e-030.2352image
ENSG00000276234.3,TADA2AUCECEHT.1864EAG2.2761e-040.2752image
chr17:37477477-37478150:+UCSCCT007093EER1.6703e-030.4106image
ENSG00000276234.3,TADA2AUCSCCT007093EAG1.6703e-030.4106image
ENSG00000276234.3,TADA2AUVMBicalutamideEAG2.4873e-02-0.2643image
chr17:37477477-37478150:+UVMBicalutamideEER2.4873e-02-0.2643image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType